SCHEMBL3392232

SCHEMBL3392232

Cc1cnc(CBr)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
CCR1 P32246 2/20 0.37
CCR5 P51681 2/20 0.37
CCR8 P51685 2/20 0.37
AGBL2 Q5U5Z8 2/20 0.35
CXCR4 P61073 2/20 0.33
CYP1A2 P05177 1/20 0.33
ERBB2 P04626 1/20 0.33
UHRF1 Q96T88 1/20 0.32
NNMT P40261 1/20 0.32
HDAC6 Q9UBN7 1/20 0.31
GABRA1 P14867 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30
GABRA5 P31644 1/20 0.30
GABRA3 P34903 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27641246 0.83 NOS3 (0.43) NOS3NOS1NOS2HSP90AA1HSP90AB1
SCHEMBL24497808 0.80 CCR1 (0.35) NOS3NOS1NOS2CCR1CCR5
SCHEMBL29338673 0.80 S1PR1 (0.37) AGBL2ERBB2UHRF1CYP2A6
SCHEMBL29384905 0.79 NOS3 (0.48) NOS3NOS1NOS2HSP90AA1HSP90AB1
SCHEMBL873234 0.79 NOS3 (0.48) NOS3NOS1NOS2HSP90AA1HSP90AB1
SCHEMBL26971130 0.78 CHRM2 (0.35) NOS3NOS1NOS2CCR1CCR5
SCHEMBL24424856 0.78 CCR1 (0.34) NOS3NOS1NOS2HSP90AA1HSP90AB1
SCHEMBL13196217 0.77 NOS3 (0.46) NOS3NOS1NOS2HSP90AA1HSP90AB1
SCHEMBL17248011 0.77 NOS3 (0.46) NOS3NOS1NOS2HSP90AA1HSP90AB1
SCHEMBL1758493 0.77 NOS3 (0.46) NOS3NOS1NOS2HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed
CN-1050132-C Ginkgolide Derivatives SUNKYONG IND LTD (KR) 2000-03-08 CN disclosed
CN-1139435-A New ginkgolide derivatives and process for preparing them SUNKYONG IND LTD (KR) 1997-01-01 CN disclosed
EP-0737195-A1 NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM SUNKYONG INDUSTRIES CO., LTD. (KR) 1996-10-16 EP disclosed
US-5541183-A RESPIRATORY SYSTEM DISORDERS, SKIN DISORDERS AND PLATELET ACTIVATING FACTOR ANTAGONIST SUNKYONG INDUSTRIES CO., LTD. (KR) 1996-07-30 US disclosed
WO-1995018131-A1 NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM SUNKYONG INDUSTRIES CO., LTD. (KR) 1995-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 NOS3 4073/4885NOS1 3969/4885NOS2 3362/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 NOS3 4073/4885NOS1 3969/4885NOS2 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.